申请人:Eisai Co., Ltd.
公开号:US05849912A1
公开(公告)日:1998-12-15
A biphenyl derivative represented by the following formula (I) or a pharmacologically acceptable salt thereof: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are defined in the specification, is clinically useful for treating and ameliorating mental disorders such as cerebrovascular disorder, aggressive behavior due to senile dementia, mental excitation, poriomania, delirium, hallucination, hyperkinesia, schizophrenia, emotional disturbance, depression, neurosis, psychophysiologic disorder and anxiety neurosis. The compounds exhibit dopamine 2 receptor antagonism and/or serotonin 2 receptor antagonism.
以下是公式(I)所代表的联苯衍生物或其药理学上可接受的盐:##STR1##其中R.sup.1、R.sup.2、R.sup.3、R.sup.4和R.sup.5在规范中有定义,对于治疗和改善脑血管疾病、老年性痴呆引起的攻击性行为、精神兴奋、狂躁症、幻觉、多动症、精神分裂症、情绪紊乱、抑郁症、神经症、心理生理障碍和焦虑症等精神障碍具有临床上的用途。这些化合物表现出多巴胺2受体拮抗作用和/或5-羟色胺2受体拮抗作用。